Association between Treatment for Localized Prostate Cancer and Mental Health Outcomes
Year: 2022
Type: article
Abstract: PURPOSE: We aimed to compare patient-reported mental health outcomes for men undergoing treatment for localized prostate cancer longitudinally over 5 years. MATERIALS AND METHODS: We conducted a prospective population-based analysis using the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study. Patient-reported depressive symptoms (Centers for Epidemiologic Studies Depression [CES-D]) and domains of the Medical Outcomes Study 36-item Short Form survey evaluating emotional well-being and energy/fatigue were assessed through 5 years after treatment with surgery, radiotherapy (with or without androgen deprivation therapy) and active surveillance. Regression models were adjusted for outcome-specific baseline function, demographic and clinicopathological characteristics, and treatment approach. RESULTS: A total of 2,742 men (median [quartiles] age 64 [59-70]) met inclusion criteria. Baseline depressive symptoms, as measured by the CES-D, were low (median 4, quartiles 1-8) without differences between groups. We found no effect of treatment modality on depressive symptoms (p=0.78), though older age, poorer health, being unmarried and baseline CES-D score were associated with declines in mental health. There was no clinically meaningful association between treatment modality and scores for either emotional well-being (p=0.81) or energy/fatigue (p=0.054). CONCLUSIONS: This prospective, population-based cohort study of men with localized prostate cancer showed no clinically important differences in mental health outcomes including depressive symptoms, emotional well-being, and energy/fatigue according to the treatment received (surgery, radiotherapy, or surveillance). However, we identified a number of characteristics associated with worse mental health outcomes including: older age, poorer health, being unmarried, and baseline CES-D score which may allow for early identification of patients most at risk of these outcomes following treatment.
Source: The Journal of Urology
Authors: Amy N. Luckenbaugh, Christopher J. D. Wallis, Li-Ching Huang, Daniela Wittmann, Zachary Klaassen, Zighuo Zhao, Tatsuki Koyama, Aaron A. Laviana, Ralph Conwill, Michael Goodman, Ann S. Hamilton, Xiao-Cheng Wu, Lisa E. Paddock, Antoinette Stroup, Matthew R. Cooperberg, Mia Hashibe, Brock B. O’Neil, Sherrie H. Kaplan, Sheldon Greenfield, Karen E. Hoffman, David F. Penson, Daniel A. Barocas
Institutions: Vanderbilt University Medical Center, University of Michigan, Michigan Medicine, Augusta University, The University of Texas at Austin, Vanderbilt-Ingram Cancer Center, Emory University, University of Southern California, Louisiana State University Health Sciences Center New Orleans, Rutgers Health, Rutgers Cancer Institute, University of California, San Francisco, University of Utah, University of Utah Health Care, University of California, Irvine, The University of Texas MD Anderson Cancer Center
Language: English
Topic: Cancer survivorship and care
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4205397860